Biotech Values

[biomaven0]

I personally think VVUS still has a decent shot of approval - not by the PDUFA date, but after the FDA has reviewed 2-year safety data.

I've never really understood the enthusiasm for Contrave compared with Qnexa. After all both of Contrave's constituents have black box warnings (for hepatic tox and suicidality respectively) whereas neither of Qnexa's components has a black box.

Peter